CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases

被引：6

作者：

Chevalier, Kevin ^{[1
]}

Genin, Michael ^{[2
]}

Jean, Thomas Petit ^{[3
]}

Avouac, Jerome ^{[4
]}

Flipo, Rene-Marc ^{[5
]}

Georgin-Lavialle, Sophie ^{[6
]}

El Mahou, Soumaya ^{[7
]}

Pertuiset, Edouard ^{[8
]}

Pham, Thao ^{[9
]}

Servettaz, Amelie ^{[10
]}

Marotte, Hubert ^{[11
]}

Domont, Fanny ^{[12
]}

Chazerain, Pascal ^{[13
]}

Devaux, Mathilde ^{[14
]}

Mekinian, Arsene ^{[15
]}

Sellam, Jeremie ^{[16
]}

Fautrel, Bruno ^{[17
]}

Rouzaud, Diane ^{[18
]}

Ebstein, Esther ^{[19
]}

Costedoat-Chalumeau, Nathalie ^{[20
]}

Richez, Christophe ^{[21
]}

Hachulla, Eric ^{[22
]}

Mariette, Xavier ^{[1
]}

Seror, Raphaele ^{[1
]}

机构：

[1] Univ Paris Saclay, Hop Bicetre, Ctr Immunol Viral Infect & Autoimmune Dis, INSERM,UMR 1184,Dept Rheumatol,AP HP, Le Kremlin Bicetre, France

[2] Univ Lille, CHU Lille, ULR METRICS Evaluat Technol St & Prat Med 2694, Lille, France

[3] AP HP, Dept Innovat & Donnees, Paris, France

[4] Cochin Hosp, Rheumatol A, Paris, France

[5] Univ Lille, Rheumatol, Lille, France

[6] Tenon Hosp, Internal Med, Paris, France

[7] Hosp Ctr Tourcoing, Rheumatol, Tourcoing, France

[8] Hosp Rene Dubos, Rheumatol, Pontoise, France

[9] Hosp St Marguer, Rheumatol, Marseille, France

[10] Hosp Robert Debre, Internal Med, Infect Dis & Clin Immunol, Reims, France

[11] Univ Hosp St Etienne, Rheumatol, St Priest En Jarez, France

[12] Univ Hosp Pitie Salpetriere Charles Foix, Internal Med & Clin Immunol, Paris, France

[13] Hop Croix St Simon, Rheumatol & Internal Med, Paris, France

[14] St Germain En Laye Intercommunal Hosp Ctr, Internal Med, Poissy, France

[15] Hosp St Antoine, AP HP, Internal Med, Paris, France

[16] Hosp St Antoine, AP HP, Rheumatol, Paris, France

[17] Sorbonne Univ, Pitie Salpetriere Hosp, Pierre Louis Inst Epidemiol & Publ Hlth, Dept Rheumatol,AP HP,INSERM,UMRS 1136, Paris, France

[18] Bichat Claude Bernard Hosp, Internal Med, Paris, France

[19] Bichat Claude Bernard Hosp, Rheumatol, Paris, France

[20] Cochin Hosp, Internal Med, Paris, France

[21] Chu Bordeaux Site Pellegrin, Rheumatol, Bordeaux, France

[22] Univ Lille, Inst Translat Res Inflammat, Referral Ctr Ctr Rare Syst Autoimmune Dis North &, Dept Internal Med & Clin Immunol,CHU Lille,INSERM,, Lille, France

来源：

FRONTIERS IN MEDICINE | 2023年 / 10卷

关键词：

COVID-19; auto-immune diseases; inflammatory rheumatic diseases; rituximab; lupus; vasculitis; rheumatic and musculoskeletal diseases; CLINICAL CHARACTERISTICS; HOSPITALIZED-PATIENTS; OUTCOMES; PNEUMONIA; THERAPY;

D O I：

10.3389/fmed.2023.1152587

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IntroductionAutoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death. Materials and methodsTwo databases were analyzed: the EDS (Entrepot des Donnees de Sante, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case-control study within the EDS database to compare AIRD cases and non-AIRD controls. ResultsAmong 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08-1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68-1.81)]. ConclusionIn this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.

引用

页数：15

共 68 条

[1] A comparison of 12 algorithms for matching on the propensity score
Austin, Peter C.
[J]. STATISTICS IN MEDICINE, 2014, 33 (06) : 1057 - 1069
[2] An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Austin, Peter C.
[J]. MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (03) : 399 - 424
[3] Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
Austin, Peter C.
[J]. PHARMACEUTICAL STATISTICS, 2011, 10 (02) : 150 - 161
[4] Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Austin, Peter C.
[J]. STATISTICS IN MEDICINE, 2009, 28 (25) : 3083 - 3107
[5] COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
Avouac, Jerome
Drumez, Elodie
Hachulla, Eric
Seror, Raphaele
Georgin-Lavialle, Sophie
El Mahou, Soumaya
Pertuiset, Edouard
Thao Pham
Marotte, Hubert
Servettaz, Amelie
Domont, Fanny
Chazerain, Pascal
Devaux, Mathilde
Claudepierre, Pascal
Langlois, Vincent
Mekinian, Arsene
Maria, Alexandre Thibault Jacques
Banneville, Beatrice
Fautrel, Bruno
Pouchot, Jacques
Thomas, Thierry
Flipo, Rene-Marc
Richez, Christophe
[J]. LANCET RHEUMATOLOGY, 2021, 3 (06) : E419 - E426
[6] Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab
Avouac, Jerome
Airo, Paolo
Carlier, Nicolas
Matucci-Cerinic, Marco
Allanore, Yannick
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (03)
[7] Evaluation of factors affecting the frequency and clinical course of COVID-19 in patients using anti-TNF-alpha agents
Baslilar, Seyma
Pehlivan, Ozlem
[J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2021, 67 (09): : 1286 - 1292
[8] COVID-19 INFECTIONS IN SARCOIDOSIS: A PROSPECTIVE SINGLE CENTER STUDY OF 886 SARCOIDOSIS PATIENTS
Baughman, Robert P.
Lower, Elyse E.
[J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2021, 38 (02)
[9] Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies
Betrains, Albrecht
Godinas, Laurent
Woei-A-Jin, F. J. Sherida H.
Rosseels, Wouter
Van Herck, Yannick
Lorent, Natalie
Dierickx, Daan
Compernolle, Veerle
Meyfroidt, Geert
Vanderbeke, Lore
Vergote, Valentijn
Lagrou, Katrien
Verhamme, Peter
Wauters, Joost
Vermeersch, Pieter
Devos, Timothy
Maes, Piet
Vanderschueren, Steven
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (06) : 1100 - 1105
[10] Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases
Bitoun, Samuel
Henry, Julien
Desjardins, Delphine
Vauloup-Fellous, Christelle
Dib, Nicolas
Belkhir, Rakiba
Mouna, Lina
Joly, Candie
Bitu, Marie
Ly, Bineta
Pascaud, Juliette
Seror, Raphaele
Afonso, Anne-Marie Roque
Le Grand, Roger
Mariette, Xavier
[J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 (06) : 927 - 933

← 1 2 3 4 5 6 7 →